IVOZALL

This brand name is authorized in Austria, Estonia, France, Ireland, Lithuania, Poland

Active ingredients

The drug IVOZALL contains one active pharmaceutical ingredient (API):

1 Clofarabine UNII 762RDY0Y2H - CLOFARABINE

Clofarabine is a purine nucleoside anti-metabolite. Its antitumour activity is believed to be due to 3 mechanisms. Clofarabine produces DNA polymerase inhibition resulting in termination of DNA chain elongation and/or DNA synthesis/repair and ribonucleotide reductase inhibition with reduction of cellular deoxynucleotide triphosphate (dNTP) pools. Clofarabine also produces disruption of mitochondrial membrane integrity with the release of cytochrome C and other proapoptotic factors leading to programmed cell death even in non-dividing lymphocytes. Read about Clofarabine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
IVOZALL Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01BB06	Clofarabine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BB Purine analogues
Discover more medicines within L01BB06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1806612
Country: FR	Base de données publique des médicaments	Identifier(s): 65013013
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1088965
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100396940